Similar articles

• Inhibition of platelet aggregation and thromboxane B2 production during aspirin treatment: dependence on the dose of the aggregating agent.

  De Caterina R, Giannessi D, Gazzetti P, Bernini W. De Caterina R, et al. Thromb Res. 1985 Jan 15;37(2):337-42. doi: 10.1016/0049-3848(85)90021-0. Thromb Res. 1985. PMID: 3975876 No abstract available.
• Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.

  Siess W, Roth P, Weber PC. Siess W, et al. Thromb Haemost. 1981 Jun 30;45(3):204-7. Thromb Haemost. 1981. PMID: 7025338
• Comparison of sympathomimetic amines with collagen, calcium ionophor and adenosine diphosphate in their effects on thromboxane formation of human platelet rich plasma.

  Ditter H, Matthias FR, Lasch HG. Ditter H, et al. Folia Haematol Int Mag Klin Morphol Blutforsch. 1984;111(6):761-8. Folia Haematol Int Mag Klin Morphol Blutforsch. 1984. PMID: 6083951
• Sevoflurane inhibits human platelet aggregation and thromboxane A2 formation, possibly by suppression of cyclooxygenase activity.

  Hirakata H, Ushikubi F, Toda H, Nakamura K, Sai S, Urabe N, Hatano Y, Narumiya S, Mori K. Hirakata H, et al. Anesthesiology. 1996 Dec;85(6):1447-53. doi: 10.1097/00000542-199612000-00027. Anesthesiology. 1996. PMID: 8968193
• Role of thromboxane A2.

  Ambler J, Birch J, Maguire ED, Wallis RB. Ambler J, et al. Adv Exp Med Biol. 1985;192:293-308. doi: 10.1007/978-1-4615-9442-0_21. Adv Exp Med Biol. 1985. PMID: 2939695 Review. No abstract available.